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Mapping heterogeneity in glucose uptake
in metastatic melanoma using quantitative
18F-FDG PET/CT analysis
Ellen C. de Heer1, Adrienne H. Brouwers2, Ronald Boellaard2, Wim J. Sluiter1, Gilles F. H. Diercks3,
Geke A. P. Hospers1, Elisabeth G. E. de Vries1 and Mathilde Jalving1*
Abstract
Background: Metastatic melanoma patients can have durable responses to systemic therapy and even long-term
survival. However, a large subgroup of patients does not benefit. Tumour metabolic alterations may well be involved in
the efficacy of both targeted and immunotherapy. Knowledge on in vivo tumour glucose uptake and its
heterogeneity in metastatic melanoma may aid in upfront patient selection for novel (concomitant) metabolically
targeted therapies. The aim of this retrospective study was to provide insight into quantitative 18F-fluorodeoxyglucose
positron emission tomography/computed tomography (18F-FDG PET/CT) parameters and corresponding intra-
and inter-patient heterogeneity in tumour 18F-FDG uptake among metastatic melanoma patients. Consecutive,
newly diagnosed stage IV melanoma patients with a baseline 18F-FDG PET/CT scan performed between May 2014
and December 2015 and scheduled to start first-line systemic treatment were included. Volume of interests (VOIs)
of all visible tumour lesions were delineated using a gradient-based contour method, and standardized uptake
values (SUVs), metabolically active tumour volume (MATV) and total lesion glycolysis (TLG) were determined on
a per-lesion and per-patient basis. Differences in quantitative PET parameters were explored between patient
categories stratified by BRAFV600 and RAS mutational status, baseline serum lactate dehydrogenase (LDH) levels
and tumour programmed death-ligand 1 (PD-L1) expression.
Results: In 64 patients, 1143 lesions ≥ 1 ml were delineated. Median number of lesions ≥ 1 ml was 6 (range
0–168), median maximum SUVpeak 9.5 (range 0–58), median total MATV 29 ml (range 0–2212) and median total
TLG 209 (range 0–16,740). Per-patient analysis revealed considerable intra- and inter-patient heterogeneity. Maximum
SUVs, MATV, number of lesions and TLG per patient did not differ when stratifying between BRAFV600 or RAS mutational
status or PD-L1 expression status, but were higher in the patient group with elevated LDH levels (> 250 U/l) compared
to the group with normal LDH levels (P < 0.001). A subset of patients with normal LDH levels also showed above
median tumour 18F-FDG uptake.
Conclusions: Baseline tumour 18F-FDG uptake in stage IV melanoma is heterogeneous, independent of
mutational status and cannot be fully explained by LDH levels. Further investigation of the prognostic and
predictive value of quantitative 18F-FDG PET parameters is of interest.
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Background
Novel therapies, especially immunotherapy, have revolu-
tionized the treatment of stage IV metastatic melanoma
over the past decade. One-year overall survival (OS)
rates have improved to 50–75% and a subset of patients
shows durable responses [1]. Still, a considerable num-
ber of patients do not respond, especially those with ele-
vated serum lactate dehydrogenase (LDH) levels [1].
The metabolic reprogramming that characterizes can-
cer cells may well be involved in the efficacy of antitu-
mour immune responses [2, 3]. Cancer cells metabolize
a substantial amount of the consumed glucose through
glycolysis only—even under aerobic conditions—in order
to generate sufficient biomass for rapid cellular prolifera-
tion [4, 5]. Novel therapeutic agents interfering with this
altered glucose metabolism have shown hints of antican-
cer activity in (pre)clinical studies, for example in breast
cancer, non-small cell lung cancer and glioblastoma [6,
7]. Additionally, preclinical data suggest metabolically
targeted therapies can improve antitumour immune re-
sponse and susceptibility to adjuvant chemo- and radio-
therapy [8–10]. In patients, however, such treatments
can result in toxicity in highly glucose-dependent
healthy tissues, such as the kidney [7, 11]. Furthermore,
recent in vitro studies demonstrate that not all melano-
mas rely on altered glucose metabolic pathways to the
same extent [12, 13]. This underlines the need for up-
front selection of patients with highly glucose-dependent
tumours in order to maximize the benefit of (concomi-
tant) metabolic therapies and ensure a sufficiently broad
therapeutic window.
Metastatic melanoma is clinically renowned for its high
uptake of the glucose analogue 18F-fluorodeoxyglucose
(18F-FDG) on positron emission tomography/computed
tomography (PET/CT) scans. Whole-body 18F-FDG PET/
CT is therefore part of standard care staging procedures
at baseline in stage IV disease, where it is used in a quali-
tative fashion to provide information on the presence and
location of metastases. However, quantitative 18F-FDG
PET/CT scan analysis has been completely unvisited in
stage IV melanoma so far and could provide a wealth of
knowledge on quantitative tumour glucose uptake in vivo,
potentially useful for upfront patient selection for meta-
bolically targeted therapies. The aim of this retrospective
study was to provide an overview of tumour 18F-FDG up-
take and corresponding intra- and inter-patient hetero-
geneity in metastatic melanoma patients using
quantitative 18F-FDG PET/CT scan analysis.
Patients and methods
Patients
Patients for this retrospective study were selected from a
prospectively maintained database containing all melan-
oma patients registered at the Department of Medical
Oncology of the University Medical Center Groningen
(UMCG), the Netherlands, from 2012 onwards. All pa-
tients ≥ 18 years of age with histologically proven cuta-
neous or mucosal metastatic melanoma (American Joint
Committee on Cancer [AJCC] 7th edition stage IV mel-
anoma [14]) without prior systemic treatment and with
a baseline 18F-FDG PET/CT scan performed between
May 2014 and December 2015 were eligible for inclusion
(n = 108). Exclusion criteria were unknown or inad-
equate adherence to European Association of Nuclear
Medicine (EANM) PET/CT scan acquisition guidelines
[15] (e.g. PET/CT scan not performed at our hospital)
(n = 26), no indication for start of first-line systemic
treatment within 2 months of baseline PET/CT scan (n =
10), concurrent malignancy or other malignancy within
the previous 10 years (n = 5) and/or no PET-positive le-
sions (n = 3). Ultimately, 64 patients were included (Add-
itional file 1: Figure S1). The Medical Ethics Committee
approved the study. Consultation of the local objection
registry verified that none of the selected patients had
objected to use of their personal data for research pur-
poses. Patients were pseudonymized, and data were stored
on a secured server following local data management
regulations.
18F-FDG PET/CT imaging
18F-FDG PET/CT scans were acquired using a Siemens
Biograph mCT PET/CT system (Siemens/CTI, Knox-
ville, TN) accredited by the European Association of Nu-
clear Medicine (EANM) Research Limited (EARL). Scan
acquisition and reconstructions were performed follow-
ing the recommendations of the EANM guideline for
oncology 18F-FDG imaging [15]. Patients were instructed
to fast and avoid exercise at least 4–6 h prior to intra-
venous 18F-FDG injection at an activity of 3 MBq/kg.
Serum glucose levels before tracer injection were <
8.3 mmol/l. Whole-body PET/CT scanning (from the
top of the skull to the bottom of the feet) was performed
60 min after 18F-FDG injection with 1–3 min per bed
position. Prior to the PET acquisition, patients under-
went a low-dose CT (LD-CT) scan during tidal breath-
ing for attenuation correction (80–140 kVp, quel. ref.
30 mAs and pitch of 1).
18F-FDG PET/CT scan analysis and volume of interest
delineation
All PET/CT scans were initially reported by a nuclear
medicine physician as part of routine patient care. Quanti-
tative scan analysis and identification and delineation of
all tumour lesions for this study were performed by one
investigator (EH) and verified by a board-certified nuclear
medicine physician with expertise in melanoma (AB).
PET(/CT) and gradient PET images were displayed
side-to-side, and volume of interests (VOIs) were delineated
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on the gradient PET images using a gradient-based
manual contouring method (in-house developed soft-
ware program). Gradient PET images are derived dir-
ectly from reconstructed PET images and depict the
relative change in counts between neighbouring vox-
els (Δ standardized uptake value [SUV]), which is typ-
ically the highest around tumour borders. Gradient
PET images consequently provide an image where the bor-
ders of the lesion are most intense. Use of gradient PET
data enables a (manual) VOI delineation method where le-
sion border location is independent of colour scale, in con-
trast to manual contouring on regular PET images.
Additional motives for choosing gradient-based delineation
were a lack of systematic delineation studies in metastatic
melanoma and inaccuracy of EARL-recommended semi-
automatic delineation methods for delineation of large het-
erogeneous tumour lesions or small yet highly 18F-FDG-a-
vid lesions [15].
A region of interest (ROI) was manually drawn around
each tumour lesion on consecutive transaxial slices. Sub-
sequently, the observer adjusted a %-threshold based on
maximum SUV (SUVmax) until the VOI borders opti-
mally corresponded with the location of the steepest gra-
dient on the gradient PET images as judged visually.
SUVmax, mean SUV (SUVmean), peak SUV (SUVpeak, i.e.
a 1.2-cm3 spheric region positioned to yield the highest
average value), metabolically active tumour volume
(MATV) and total lesion glycolysis (TLG, the product of
SUVmean and MATV) were determined for each VOI.
SUVs were corrected for serum glucose level and lean
body mass according to the Janmahasatian formula [15].
Lesions with an MATV < 1 ml were excluded from the
final quantitative analysis to prevent partial volume ef-
fects. PET parameters were analysed on a per-patient,
per-location and per-lesion basis. Patient’s maximum
SUV and median SUV reflect respectively the highest
and median value derived from all lesions ≥ 1 ml within
that patient. Interquartile range (IQR) SUVpeak was de-
rived from the SUVpeaks of all individual lesions delin-
eated in one patient as a measure for intra-patient
18F-FDG uptake heterogeneity. Total MATV or total
TLG equals the sum of respectively MATV or TLG of
all lesions ≥ 1 ml within that patient.
CT and brain MRI scan analysis
Previously, PET-negative (i.e. with SUVmax < 1.5) melan-
oma metastases have been described, and we excluded
three eligible patients upfront due to the presence of
only PET-negative lesions [16]. Therefore, we aimed to
evaluate the first 20 included patients for the presence
of PET-negative lesions with a diameter ≥ 1 cm on base-
line contrast-enhanced CT (ce-CT) scan performed
within 1 month of the baseline PET/CT. ce-CT scan was
available in 12 of the 20 patients and revealed only 2
additional 18F-FDG PET-negative lesions ≥ 1 cm on top
of the total of 491 PET-positive lesions > 1 ml in these
patients (0.4%). Due to this limited additional value,
ce-CT analysis was omitted for the remaining patients.
High physiological background 18F-FDG uptake prevents
accurate detection and quantification of brain metastases.
Therefore, the presence of brain lesions was additionally
evaluated on baseline cerebral MRI scans or cerebral
ce-CT. Quantitative data from brain lesions were not incor-
porated in per-patient PET parameters. When brain lesions
were measurable (longest axis on MRI > 1 cm according to
Response Assessment in Neuro-Oncology Brain Metastases
[RANO-BM] criteria [17]) and 18F-FDG-avid, SUVpeak and
SUVmax were measured.
Data acquisition
Patient and tumour characteristics, baseline serum LDH
levels and respectively tumour BRAF and RAS mutation
status were retrospectively determined from the elec-
tronic patient file. Pre-treatment serum LDH levels were
derived from the date closest to the baseline PET/CT
scan. When pre-treatment archival tumour biopsies for a
distant metastasis were available, PD-L1 immunohisto-
chemistry (IHC) was performed as previously described
elsewhere using the 22C3 anti-PD-L1 antibody (DAKO,
Merck) on Ventana BenchMark ULTRA platform [18].
Tissue derived from primary melanomas, local recur-
rences, in-transit cutaneous metastases or lymph node
metastases was excluded. Scoring was performed by two
board-certified pathologists (GFHD, NAH) and per-
formed according to the manufacturer’s instructions.
Statistical analysis
Variables were assessed for normal distribution by Q-Q
plots. Independent Mann-Whitney U tests were used to
assess differences in PET parameters between LDH, BRAF
and RAS groups, respectively, and Kruskal-Wallis tests for
differences between metastatic locations and PD-L1 ex-
pression groups. Spearman’s rank correlation was used for
the correlation between lesion MATV and SUVpeak. A P
value < 0.05 (two-sided) was considered statistically sig-
nificant. Statistical analysis was performed using SPSS Sta-
tistics, version 23.0 (IBM Corp., Armonk, NY).
Results
PET parameters on a per-patient basis
Patient characteristics are presented in Table 1. BRAFV600
mutational status did not differ between patients with nor-
mal or elevated serum LDH (42.9% vs. 57.1%; P = 0.260).
Patient’s maximum SUVpeak showed a broad range (0–58;
median 9.5) between patients (Fig. 1 and Table 2). Further-
more, intra-patient 18F-FDG uptake heterogeneity was ob-
served, with SUVpeak IQR ranging from 0 to 42.4 (median
2.1). The number of lesions, SUVs, total MATV and total
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TLG (per-patient basis) did not differ between BRAFV600
mutant vs. wild-type patients (Table 3), RAS mutated vs.
wild-type patients and BRAFV600/RAS mutant vs.
BRAFV600+RAS wild-type patients (data not shown).
Patients with an elevated LDH level (> 250 U/l) had more
lesions ≥ 1 ml (median 17 vs. 4, P < 0.001), a higher total
MATV (127 vs. 14 ml, P < 0.001), higher maximum
SUVpeak (13.3 vs. 8.7, P = 0.011), SUVmax (15.8 vs.
11.3, P = 0.026) and SUVmean (9.0 vs. 6.0, P = 0.009)
and higher total TLG (1180 vs. 67, P < 0.001) (Table 3).
Of the 13 tumour specimens that were available for
PD-L1 IHC, 4 showed < 1% PD-L1 expression, 3 1–
49% and 6 ≥ 50%. PD-L1 expression status did not
correlate with any of the PET parameters (data not
shown).
PET parameters on a per-lesion and per-location basis
In total, 3408 tumour lesions were delineated, of which
1143 had an MATV ≥ 1 ml. Median lesion SUVpeak was 5.0
(range 0–58), median MATV was 2.4 ml (range 1.0–1921)
and median TLG 11 (range 1.1–11,206) (Additional file 2:
Table S1). Lesion SUVpeak and MATV were moderately
correlated (correlation coefficient 0.521, P < 0.001). The
highest numbers of separate lesions were observed in bone
(n = 504, 44% of all lesions ≥ 1 ml), liver (n = 241, 21%) and
lymph nodes (n = 125, 11%) (Additional file 3: Figure S2a),
and total measured MATV was highest in the abdomen
(5683 ml, 39%) followed by bone (3864 ml, 27%) and lymph
nodes (2321 ml, 16%) (Additional file 3: Figure S2b). No
major differences between metastatic locations concerning
Table 1 Patient characteristics




Age (years) at baseline PET/CT 59 (45–69)
(range 25–80)
World Health Organization performance
0 45 (70.3%)
1 7 (10.9%)





Primary melanoma unknown/missing 13 (20.3%)




No. of different metastatic locationsa
1 3 (4.7%)
2 6 (9.4%)
> 2 55 (85.9%)
Organ involvement
(Sub)cutaneous 39 (60.9%)














BRAFV600 mutation 31 (48.4%)
No BRAFV600 mutation 33 (51.6%)
RAS mutation status
RAS mutationf 15 (23.4%)
No RAS mutation 49 (76.6%)
Table 1 Patient characteristics (Continued)
Characteristic All patients (n = 64)




> 1–2× ULN 23 (35.9%)
> 2× ULN 5 (7.8%)
Missing 1 (1.6%)
Interval between baseline PET/CT and LDH
measurement (days)
0 (− 7 to + 3)
(range − 39 to + 11)
Data are displayed as n (%) or median (interquartile range)
LDH lactate dehydrogenase, ULN upper limit of normal
aIncluding brain metastases
bNumber of patients with lesions in the abdominal cavity/peritoneum (n = 27;
42.2% of all patients), adrenal gland (n = 12; 18.8%), bowel (n = 6; 9.4%), spleen
(n = 3; 4.7%), kidney (n = 2; 3.1%), gallbladder (n = 1; 1.6%), stomach (n = 1;
1.6%), rectum (n = 1; 1.6%) and/or pancreas (n = 1; 1.6%)
cNumber of patients with lesions in the vaginal or nasal mucosa (n = 4; 6.3%),
myelum (n = 1; 1.6%), shoulder joint (n = 2; 3.1%), breast (n = 2; 3.1%),
pericardium (n = 3; 4.7%), heart (n = 2; 3.1%) and/or abdominal or thoracic wall
of undetermined tissue of origin (n = 2; 3.1%)
dBased on MRI brain (n = 53) or, when missing, contrast enhanced CT (n = 4)
eI.e. distinguishable from normal brain tissue
fNRAS (n = 14) and KRAS (n = 1)
gI.e. > 250 U/l
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individual lesion’s MATV and SUVpeak were observed
(Additional file 4: Figure S3).
Brain metastases were present in 22 patients, and 16
had measurable disease according to RANO-BM criteria
[17]. In 11 of these patients, brain metastases were vis-
ible as hypermetabolic lesions on 18F-FDG PET/CT. Me-
dian SUVpeak and SUVmax of these lesions were 7.2
(range 4.8–36.8) and 9.0 (6.5–45.4), respectively.
Overall survival
Following the baseline PET/CT scan, patients com-
menced standard systemic treatment consisting of either
immune checkpoint inhibition, BRAF(/MEK) inhibition
and/or dacarbazine chemotherapy. Given the various
systemic treatments used, overall survival analysis was
performed for exploratory purposes only (Kaplan-Meier
overall survival curves in Additional file 5: Figure S4).
Discussion
We show major intra- and inter-patient heterogeneity in
tumour lesion 18F-FDG uptake among metastatic melan-
oma patients. Presence of tumours with above median
18F-FDG uptake was independent of tumour mutational
status and did not fully coincide with high serum LDH
level. This suggests that tumour 18F-FDG uptake is an in-
dependent feature and that 18F-FDG PET parameters
might be suitable as a selection tool for novel metabolic
therapies.
This is the first large study providing an overview of
intra- and inter-patient differences in tumour glucose
consumption in metastatic melanoma patients using
quantitative whole-body imaging of 18F-FDG uptake.
Previous melanoma studies on 18F-FDG PET/CT im-
aging focused on its diagnostic accuracy for qualitative
lesion detection and/or used quantitative parameters de-
rived from the primary melanoma or only a limited
number of (the most intense) lesions for response evalu-
ation or prognostic models. By performing quantitative
evaluation of all tumour lesions, we highlight the utility
of 18F-FDG PET/CT in demonstrating heterogeneity of
glucose uptake among metastatic melanoma patients.
Preliminary estimates of the influence of tumour
18F-FDG uptake on survival support further prospective
investigation as a prognostic biomarker.
Compared to previous studies, we found a higher pro-
portion of bone metastases and a lower incidence of
lung and soft tissue metastases. Two previous studies in
metastatic melanoma using 18F-FDG PET/CT ± other
Fig. 1 Individual tumour lesions (≥ 1 ml) and their SUVpeak displayed per patient. For each patient (x-axis; n = 64), individual tumour lesions are plotted
against their SUVpeak (left y-axis). Grey shaded bars represent the patient’s total MATV (right y-axis). The heatmap displays respectively the patient’s LDH
level and tumour BRAF and NRAS status and PD-L1 expression. Three patients are not displayed since they only had lesions < 1 ml, which resulted in
SUVs, a MATV and TLG of 0. LDH lactate dehydrogenase, LN lymph node, PD-L1 programmed death-ligand 1, ULN upper limit of normal
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imaging methods qualitatively report metastases predom-
inantly to the lung, liver, lymph nodes and skin/soft tissue
[19, 20]. This difference might be explained by differing
patient populations, especially since our study also in-
cluded patients with an unknown primary melanoma and
subsequent widespread (skeletal) metastases (n = 8), as op-
posed to the study performed by Schoenewolf et al. [19].
Furthermore, we excluded lesions with an MATV < 1 ml
to minimize partial volume effects. Three patients had
only lesions with an MATV < 1 ml, which all concerned
metastases in the lymph nodes, lung, subcutis and/or
muscles. The small MATV at these locations, resulting in
the exclusion of these lesions for the analysis, further ex-
plains the smaller fraction of soft tissue, lymph node and
subcutaneous lesions in our PET-based study.
BRAFV600 mutant melanoma cells rely heavily on glycoly-
sis with high glycolytic rates induced by activation of the
mitogen-activated protein kinase (MAPK) pathway [21, 22].
BRAFV600 wild-type melanomas (approximately 50% of
melanomas) often have alternative mutations in the
MAPK-pathway including RAS orMEK1/2 that are also as-
sociated with glycolytic dependency and increased glucose
uptake [23–25]. In thyroid carcinoma, BRAFV600E tumours
show increased expression of glucose transporter (GLUT)
and higher SUVs compared to BRAFV600 wild-type tumours
[26, 27]. We found no difference in tumour glucose uptake
and MATV between patients with and without a BRAFV600
or RAS mutation. Overexpression of other proteins
Table 2 18F-FDG PET tumour lesion parameters on a per-patient
basis
All patients (n = 64) Range
No. of lesions
All 18 (11–51) 1–417
≥ 1 mla,b 6 (2–16) 0–168
SUVpeak
Maximum 9.5 (5.5–15.5) 0–58.3
Median 4.3 (3.2–8.6) 0–25.2
SUVpeak interquartile range
c 2.1 (0–5.1) 0–42.4
SUVmax
Maximum 11.8 (7.3–18.0) 0–67.2
Median 6.1 (4.1–11.5) 0–37.6
SUVmean
Maximum 7.2 (4.7–10.7) 0–30.2
Median 4.3 (3.0–7.3) 0–18.5
Total MATV (ml) 29.2 (12.2–234) 0–2212
Total TLG 209 (46.2–1510) 0–16,740
Data are displayed as median (interquartile range)
aThree patients had only lesions < 1 ml
bI.e. all lesions included in quantitative analyses
cI.e. interquartile range of the different SUVpeaks measured within one patient,
measure of intra-patient heterogeneity
Table 3 18F-FDG PET lesion parameters on a per-patient basis, stratified by LDH or BRAFV600 mutation status
LDH groupsa P BRAFV600 groups P
Normalb (n = 35) Elevated (n = 28) Wild-type (n = 33) Mutant (n = 31)
No. of lesions
All 13 (7–17) 46 (20–140) < 0.001 17 (10–34) 18 (11–64) 0.510
≥ 1 mlc 4 (2–6) 17 (7–48) < 0.001 6 (3–14) 6 (2–26) 0.984
SUVpeak
Maximum 8.7 (4.4–13.1) 13.3 (7.1–23.5) 0.011 10.1 (5.6–18.9) 8.8 (5.2–13.9) 0.310
Median 3.9 (2.7–7.4) 5.5 (3.5–8.9) 0.203 5.3 (3.3–9.0) 4.0 (3.2–8.3) 0.317
SUVpeak interquartile range
d 1.2 (0–3.3) 3.3 (1.5–6.7) 0.002 2.7 (0–5.1) 2.0 (0–4.7) 0.380
SUVmax
Maximum 11.3 (6.1–16.6) 15.8 (9.0–27.7) 0.026 13.0 (7.3–22.2) 11.6 (7.2–17.4) 0.344
Median 5.3 (3.7–9.4) 8.0 (4.9–12.0) 0.171 7.4 (4.5–11.7) 5.3 (4.0–11.7) 0.394
SUVmean
Maximum 6.0 (4.1–8.7) 9.0 (6.1–15.4) 0.009 8.4 (4.7–12.3) 6.9 (4.7–8.8) 0.274
Median 3.9 (2.8–6.2) 5.3 (3.4–7.6) 0.128 4.8 (3.2–7.9) 3.9 (2.9–7.1) 0.256
Total MATV (ml) 14 (6–65) 127 (29–512) < 0.001 44 (10–185) 29 (13–238) 0.861
Total TLG 67 (18–448) 1180 (200–2998) < 0.001 281 (43–1541) 199 (64–1568) 0.984
Data are displayed as median (interquartile range)
LDH lactate dehydrogenase
aOne patient had a missing LDH value
bThree patients with normal LDH had only lesions < 1 ml
cAll lesions included in subsequent quantitative analyses
dInterquartile range of the different SUVpeaks measured within one patient, measure of intra-patient heterogeneity
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stimulating glucose consumption in the BRAF/RAS
wild-type population may explain this observation. Poten-
tially relevant proteins include MEK1/2 (8% of melanomas),
involved in the MAPK-pathway [25], and mTOR (10.4% of
primary melanomas) or PDK1, involved in the
PI3K-Akt-mTOR pathway [28, 29]. Furthermore, patient’s
BRAF status is determined based on one tumour tissue
sample, not uncommonly the (excised) primary melanoma,
and consequently does not necessarily represent the muta-
tional status of all metastases within a patient [30].
Patients with an elevated serum LDH level—a
well-established prognostic biomarker for both worse sur-
vival and poor treatment response—had higher tumour
18F-FDG uptake as well as higher metabolic tumour vol-
ume compared to those with normal LDH levels. How-
ever, we also observed tumours with high 18F-FDG in
patients with (still) relatively low MATV and normal LDH
levels. Moreover, several patients with an elevated LDH
level had only tumour lesions with relatively low 18F-FDG
uptake. LDH is a cytoplasmic enzyme that catalyses the
interconversion of pyruvate and lactate downstream of
glycolysis. A high LDH serum level is generally regarded
as a marker of cell damage or necrosis, but the exact
source of serum LDH levels is unknown. The biological
role of LDH in glucose metabolism has also been sug-
gested as an underlying mechanism and in vitro data sug-
gest differential reliance on aerobic glycolysis and
oxidative phosphorylation between patients with normal
and elevated serum LDH [3, 13]. Unfortunately, meaning-
ful multivariate approaches to unravel the interrelations
between tumour volume, tumour glucose consumption
and a proposed metabolic factor underlying serum LDH
levels were prohibited by collinearity in our data.
Metabolic targeting may constitute a promising
novel approach for patients with tumours with high
glucose uptake identified by 18F-FDG PET. Further-
more, glycolysis results in extracellular accumulation
of lactate and low pH, which are known to impair im-
mune cell function and contribute to an immunosup-
pressive tumour microenvironment [3, 5]. Metabolic
interference combined with immunotherapy might
thus be attractive for improving immunotherapy re-
sponse, for instance in the poorly responding group of
metastatic melanoma patients with elevated LDH
levels. Metabolic cancer therapies have numerous spe-
cific metabolic targets and so far, studies into the cor-
relation between melanoma expression of specific
glycolytic transporters and enzymes, such as GLUT1
and hexokinase (HK), and 18F-FDG uptake are limited
and contradictive [31, 32]. New studies are needed to
integrate tumour 18F-FDG uptake and other clinical
biomarkers with tumour dependence upon specific
metabolic pathways and targetable metabolic trans-
porters and enzymes.
Limitations of our study include its retrospective nature
and patient heterogeneity in treatment, which allowed only
preliminary estimates of the influence of tumour PET pa-
rameters on survival. The lack of ce-CT in several patients
and its more detailed anatomical lesion information could
have resulted in erroneous inclusion of physiological
PET-positive lesions or exclusion of malignant PET-positive
lesions, respectively. Since tumour measurements were per-
formed on PET images only, necrotic areas (observed in
three patients) and brain metastases (n = 22) are not incor-
porated in the MATV.
Conclusions
Tumour 18F-FDG uptake is heterogeneous within and
among metastatic melanoma patients. High 18F-FDG up-
take is independent of BRAF/RAS mutation status and
does not fully correlate with serum LDH levels. This
suggests 18F-FDG PET metabolic parameters could serve
as an (additional) selection tool for melanoma patients
potentially benefiting from metabolic therapies. Further
investigation of the prognostic and predictive value of
quantitative 18F-FDG PET parameters is warranted.
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the selection of eligible patients. (DOCX 547 kb)
Additional file 2: Table S1. 18F-FDG PET lesion parameters on a per-lesion
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stratified by normal vs. elevated (i.e. > 250 U/l) LDH levels and patient
population median of respectively maximum SUVpeak (A), total MATV (B)
and total TLG (C). LDH = lactate dehydrogenase. (DOCX 271 kb)
Abbreviations
18F-FDG: 18F-fluorodeoxyglucose; AJCC: American Joint Committee on
Cancer; Akt: Protein kinase B; ce: Contrast-enhanced; CT: Computed
tomography; EANM: European Association of Nuclear Medicine; EARL: EANM
Research Limited; HK: Hexokinase; IHC: Immunohistochemistry; LD: Low-dose;
LDH: Lactate dehydrogenase; MAPK: Mitogen-activated protein kinase;
MATV: Metabolically active tumour volume; MEK: Mitogen-activated protein
kinase kinase; MRI: Magnetic resonance imaging; mTOR: Mammalian target of
rapamycin; PD-L1: Programmed death-ligand 1; PET: Positron emission
de Heer et al. EJNMMI Research           (2018) 8:101 Page 7 of 9
tomography; PI3K: Phosphoinositide 3-kinase; RANO-BM: Response Assessment
in Neuro-Oncology Brain Metastases; ROI: Region of interest; SUV: Standardized
uptake value; TLG: Total lesion glycolysis; UMCG: University Medical Center
Groningen; VOI: Volume of interest
Acknowledgements
The authors acknowledge JH van Snick and NA ‘t Hart for their technical
assistance.
Funding
EH received a Van Walree Grant of the Royal Netherlands Academy of Arts
and Sciences to present these findings at the AACR Metabolism and Cancer
2018 Conference.
Availability of data and materials
The datasets used and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
EH, AB, RB, WS, GH, EV and MJ contributed to the study concepts and
design. EH, AB, RB, GD and MJ contributed to the data acquisition and
quality control of the data. EH, AB, RB, WS, GD, GH, EV and MJ contributed to
the data analyses and interpretation. EH, AB, RB, WS and MJ contributed to
the statistical analysis. EH, AB, RB and MJ contributed to the manuscript
preparation. EH, AB, RB, WS, GD, EV, GH and MJ contributed to the manuscript
review and editing. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This retrospective study was approved by the Institutional Medical Ethics
Committee (case number 2016/474), and the need for informed consent was
waived. Consultation of the local objection registry verified that none of the





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medical Oncology, University Medical Center Groningen,
University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen,
The Netherlands. 2Department of Nuclear Medicine and Molecular Imaging,
University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands. 3Department of Pathology, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands.
Received: 10 September 2018 Accepted: 31 October 2018
References
1. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al.
Survival of patients with advanced metastatic melanoma: the impact of
novel therapies. Eur J Cancer. 2016;53:125–34.
2. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al.
LDHA-associated lactic acid production blunts tumor immunosurveillance
by T and NK cells. Cell Metab. 2016;24:657–71.
3. Blank CU, Haanen JB, Ribas A, Schumacher TN. The “cancer immunogram”.
Science. 2016;352:658–60.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science. 2009;324:
1029–33.
5. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism.
Cell Metab. 2016;23:27–47.
6. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al.
Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med.
2010;2:31ra34.
7. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer
metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14:11–31.
8. Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A,
et al. Targeting hexokinase 2 enhances response to radio-chemotherapy in
glioblastoma. Oncotarget. 2016;7:69518–35.
9. Bénéteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, et al.
Combination of glycolysis inhibition with chemotherapy results in an
antitumor immune response. Proc Natl Acad Sci U S A. 2012;109:20071–6.
10. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for
cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.
11. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, et al.
Dichloroacetate should be considered with platinum-based chemotherapy
in hypoxic tumors rather than as a single agent in advanced non-small cell
lung cancer. J Cancer Res Clin Oncol. 2014;140:443–52.
12. Shestov AA, Mancuso A, Lee SC, Guo L, Nelson DS, Roman JC, et al. Bonded
cumomer analysis of human melanoma metabolism monitored by 13C NMR
spectroscopy of perfused tumor cells. J Biol Chem. 2016;291:5157–71.
13. Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, et al.
Importance of glycolysis and oxidative phosphorylation in advanced
melanoma. Mol Cancer. 2012;11:76.
14. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR,
et al. Final version of 2009 AJCC melanoma staging and classification. J Clin
Oncol. 2009;27:6199–206.
15. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W,
et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version
2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
16. Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC.
High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic
information for detection of metastases. Radiology. 2007;244:566–74.
17. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al.
Response assessment criteria for brain metastases: proposal from the RANO
group. Lancet Oncol. 2015;16:270–8.
18. Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V,
et al. Use of the 22C3 anti–PD-L1 antibody to determine PD-L1
expression in multiple automated immunohistochemistry platforms.
PLoS One. 2017;12:e0183023.
19. Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, Scherrer E, et al.
Clinical implications of distinct metastasizing preferences of different
melanoma subtypes. Eur J Dermatology. 2014;24:236–41.
20. Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, et al.
Prognostic relevance of lactate dehydrogenase and serum S100 levels in
stage IV melanoma with known BRAF mutation status. Br J Dermatol. 2016;
174:823–30.
21. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, et al.
Dysfunctional oxidative phosphorylation makes malignant melanoma
cells addicted to glycolysis driven by the (V600E)BRAF oncogene.
Oncotarget. 2013;4:584–99.
22. Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, et al.
Dependence on glycolysis sensitizes BRAF-mutated melanomas for
increased response to targeted BRAF inhibition. Sci Rep. 2017;7:42604.
23. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature. 2010;468:973–7.
24. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number
defines metabolic reprogramming and therapeutic susceptibilities. Nature.
2016;531:110–3.
25. Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, et
al. Beyond the BRAFV600E hotspot: biology and clinical implications of rare
BRAF gene mutations in melanoma patients. Br J Dermatol. 2017;177:936–44.
26. Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH. Clinicopathological
characteristics including BRAF V600E mutation status and PET/CT findings in
papillary thyroid carcinoma. Clin Endocrinol. 2017;87:73–9.
27. Yoon M, Jung SJ, Kim TH, Ha TK, Urm SH, Park JS, et al. Relationships
between transporter expression and the status of BRAF V600E mutation and
F-18 FDG uptake in papillary thyroid carcinomas. Endocr Res. 2016;41:64–9.
28. Yan K, Si L, Li Y, Wu X, Xu X, Dai J, et al. Analysis of mTOR gene aberrations
in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR
pathway inhibitors. Clin Cancer Res. 2016;22:1018–27.
de Heer et al. EJNMMI Research           (2018) 8:101 Page 8 of 9
29. Pópulo H, Caldas R, Lopes JM, Pardal J, Máximo V, Soares P. Overexpression
of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate
for cutaneous melanoma therapy. Expert Opin Ther Targets. 2015;19:733–45.
30. Riveiro-Falkenbach E, Santos-Briz A, Ríos-Martín JJ, Rodríguez-Peralto JL.
Controversies in intrapatient melanoma BRAFV600E mutation status. Am J
Dermatopathol. 2017;39:291–5.
31. Park SG, Lee JH, Lee WA, Han KM. Biologic correlation between glucose
transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
Nucl Med Biol. 2012;39:1167–72.
32. Yamada K, Brink I, Bissé E, Epting T, Engelhardt R. Factors influencing [F-18]
2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role
of proliferation rate, viability, glucose transporter expression and hexokinase
activity. J Dermatol. 2005;32:316–34.
de Heer et al. EJNMMI Research           (2018) 8:101 Page 9 of 9
